Rucaparib in Nonmetastatic prOstAte With BRCAness

Part of paid clinical trials in Salt Lake City, Utah.

Sponsor
University of Utah
Study ID
NCT03533946
Phase
PHASE2
Status
Terminated

Conditions

Eligibility Criteria

Sex
MALE
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Rucaparib — DRUG
    Treatment with rucaparib will begin on Cycle 1 Day 1 and continue at 600 mg twice daily. Therapy continues until Prostate Specific Antigen (PSA) progression or intolerable toxicities.

Study Details

This is a single arm, open label, phase II trial to assess efficacy of rucaparib.

Key Dates

Start date
May 20, 2019
Status verified
Feb 2024
Primary completion
Jan 12, 2023
Completion
Jan 12, 2023

Study Design

Enrollment
7 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Rucaparib, all participants
    Single Arm study, all participants will get rucaparib

Primary Outcome Measure

Prostate Specific Antigen Progression Free Survival [ Time Frame: From baseline to up to 2 years after study treatment discontinuation; actual max approximately 42 months ]

Locations (1)

FacilityCityStateZIPSite coordinators
Huntsman Cancer InstituteSalt Lake CityUtah84112-

Find similar trials in Salt Lake City, UT

By condition
Prostate cancer
By specialty
OncologyProstate oncologyMen's healthUrology
By research site
Huntsman Cancer Institute· Salt Lake City, UT

Related Studies